VIGL Vigil Neuroscience Inc. Forward P/E Multiple
Vigil Neuroscience focuses on developing microglia-modulating drugs for brain degeneration and the therapy of rare pathologies. The company's forward P/E clearly demonstrates the value of expected earnings, while 0.00 reflects the latest value of the metric. The diversification of immunological approaches expands its presence in neuromedicine, and its independence from macroeconomic factors transforms the asset into a resilient defensive tool.
Financial and market metric breakdowns for Vigil Neuro (VIGL)
- stock quotes and analyst forecast:
- market capitalization data:
- book capitalization information:
- debt and liquidity data:
Total Debt to Equity Ratio Vigil Neuroscience|VIGL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Vigil Neuroscience|VIGL - Company Aggregate Debt|Debts to Book Capitalization Vigil Neuroscience Inc.|VIGL - Long-Term Debt|Company Current Liabilities Vigil Neuroscience|Quick Liquidity vigilneuro.com
- earnings and market ratios statistics:
VIGL - Final Profit|Expected Profit Vigil Neuroscience|VIGL - Market Cap to Earnings|Future Price to Earnings Vigil Neuroscience|VIGL - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Vigil Neuroscience Inc.|VIGL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Vigil Neuroscience|VIGL - Net earnings per share for the last four quarters|Quarterly EPS earnings growth vigilneuro.com|VIGL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Vigil Neuroscience
- revenue and sales proceeds data:
Summary company analytics:Vigil Neuroscience, Inc.
The forward P/E ratio dynamics for Vigil Neuroscience (VIGL) reflect market expectations regarding the implementation of robotic screening and the automation of TREM2 receptor data analysis. This indicator correlates the current share price with the consensus forecast for future earnings per share, allowing investors to assess the level of optimism priced in and the risk of a correction should the pace of commercialization deviate from expectations.
Competitors of Vigil Neuroscience (VIGL)
Forward P/E Multiple BIIB|Market Cap to Projected Earnings Neurocrine|Forward P/E Multiple RGC (Regencell)|Forward Price to Earnings Multiple Axsome Corp|ACADIA Pharmaceuticals - Forward P/E Multiple|Market Cap to Projected Earnings xenon-pharma.com XENE|Viking Therapeutics, Inc. (VKTX) - Future Price to Earnings|SUPN (Supernus Pharmaceuticals, Inc.) - Future Price to Earnings|Projected Price to Earnings CPRX|DNLI: Future Price to Earnings Multiple|Future Price to Earnings Harmony Biosciences (HRMY)|biohavenpharma.com - Price to Future Earnings Ratio|Forward P/E Multiple AMLX (Amylyx Pharmaceuticals, Inc.)|Trevi Therapeutics Inc (TRVI) - Projected Price to Earnings Ratio|PRAX: Projected Price to Earnings|AVXL - Forward P/E Multiple|CeriBell, Inc. (CBLL) - Future Price to Earnings|Prothena - Future Price to Earnings Multiple|Future Price to Earnings Alector Inc.|Projected Price to Earnings Ratio Annexon Biosciences ANNX|Future Price to Earnings Omeros Corporation (OMER)|Market Cap to Projected Earnings Neurogene Therapeutics|Forward P/E Multiple ACIU (AC Immune)|VYGR - Projected Price to Earnings|Neumora Therapeutics, Inc. - Forward P/E Multiple|Market Cap to Projected Earnings Scilex Holding SCLX|TVGN: Forward P/E Multiple|Projected Price to Earnings Ratio Alpha Cognition Inc. (ACOG)|Future Price to Earnings Cognition Therapeutics|Price to Future Earnings Ratio IKT (inhibikase.com)|Forward P/E Multiple SAVA|Projected Price to Earnings assertiotx.com ASRT|Forward P/E Multiple COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Projected Price to Earnings Ratio|OVID: Projected Price to Earnings|ABOS: Future Price to Earnings|CRVO: Forward P/E Multiple|ATHE - Market Cap to Projected Earnings|CLNN (Clene Inc) - Forward P/E Multiple|PEPG - Forward Price to Earnings Multiple|Future Price to Earnings Jupiter Neurosciences Inc (JUNS)|Future Price to Earnings RLMD (relmada.com)|Future Price to Earnings Annovis Bio ANVS|GRCE: Price to Future Earnings Ratio|Firefly Neuroscience Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Klotho Neurosciences Inc|NRSN (neurosense-tx.com) - Projected Price to Earnings|revivapharma.com (RVPH) - Forward P/E Multiple|Future Price to Earnings MetaVia Inc.|NRXS: Future Price to Earnings Multiple|Future Price to Earnings Helius Medical (HSDT)|PASG - Projected Price to Earnings Ratio|Neuphoria Therapeutics - Projected Price to Earnings|minervaneurosciences.com - Future Price to Earnings|Athira Pharma - Forward P/E Multiple|Market Cap to Projected Earnings Addex Therapeutics Ltd. ADXN|ALZN: Forward P/E Multiple|Forward Price to Earnings Multiple Cyclerion Therapeutics, Inc. CYCN|PTIX (Protagenic Therapeutics Inc.) - Forward P/E Multiple|Pasithea (KTTA) - Market Cap to Projected Earnings|Future Price to Earnings Cortigent, Inc. (CRGT)|Future Price to Earnings ATXI (Avenue Therapeutics Inc.)|Brainstorm Cell Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple CARA|CHRO - Future Price to Earnings|ELYM (Eliem Therapeutics) - Price to Future Earnings Ratio|ITCI: Forward P/E Multiple|Projected Price to Earnings Ratio Longboard Pharmaceuticals Inc (LBPH)|Projected Price to Earnings MRNS|Forward P/E Multiple NKGen Biotech Corp|Future Price to Earnings NeuroBo Pharmaceuticals (NRBO)|SAGE (sagerx.com) - Future Price to Earnings Multiple|Future Price to Earnings Synaptogenix SNPX|Trevena Inc. (TRVN) - Projected Price to Earnings Ratio|WENA - Future Price to Earnings|Market Cap to Projected Earnings Cerevel Corp CERE
